Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Eugene MacKie

Otolaryngology Edinburg, TX Medical Doctor

NPI 1407801103 CMS profile 198986

2709 Cornerstone Blvd, Edinburg, TX 78539

Open in the dashboard

General payments

$3,915

154 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Eugene MacKie of Edinburg, TX is reported in the CMS Open Payments database as having received $3,915 across 154 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $850 27
2022 General $833 37
2021 General $532 28
2020 General $306 16
2019 General $1,393 46

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eugene MacKie
  • Otolaryngology median
  • Middle half of Otolaryngology
  • National median

In program year 2025, general payments to Eugene MacKie were reported at $0. Among 6,588 Otolaryngology profiles paid that year, the median was $317 and the middle half received between $125 and $815.

Show as a table
Year Eugene MacKie Otolaryngology median Middle half National median
2019 $1,393 $194 $82–$512 $163
2020 $306 $118 $42–$280 $114
2021 $532 $167 $63–$444 $132
2022 $833 $216 $84–$545 $149
2023 $850 $235 $93–$588 $160
2024 $0 $280 $111–$699 $164
2025 $0 $317 $125–$815 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Stryker Corporation $1,608 65 payments
  2. Medtronic, Inc. $879 29 payments
  3. Medtronic USA, Inc. $596 22 payments
  4. Acclarent, Inc $252 7 payments
  5. Regeneron Healthcare Solutions, Inc. $250 13 payments
  6. OptiNose US, Inc. $130 6 payments
  7. Phadia US Inc. $89 5 payments
  8. GlaxoSmithKline, LLC. $50 3 payments
  9. Arbor Pharmaceuticals, Inc. $26 2 payments
  10. Genzyme Corporation $17 1 payment
  11. Other $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $3,915 154 payments
Products named General payments · program years 2019–2023
  1. SPIROX - LATERA $561 12 payments
  2. PROPEL $528 13 payments
  3. ENTELLUS - XPRESS ENT DILATION SYSTEM $337 14 payments
  4. NUVENT Sinus Surgery $334 15 payments
  5. FUSION $320 15 payments
  6. XPRESS ENT DILATION SYSTEM $289 11 payments
  7. NUVENT Sinus Surgery $263 6 payments
  8. DUPIXENT $250 13 payments
  9. CLARIFIX CRYOTHERAPY DEVICE $217 7 payments
  10. LATERA $199 7 payments
  11. Other $1,202 58 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

154 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otolaryngology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record